Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Summary

Introduction: Warrick Bishop hosts this episode to discuss an unconventional application of statin therapy—using statins alongside chemotherapy to reduce cardiotoxicity in cancer patients. The episode focuses on the STOP-CA trial, a landmark double-blind, placebo-controlled study examining whether atorvastatin can protect the heart from damage caused by anthracycline chemotherapy in lymphoma patients.

Key Takeaways:

• Anthracycline chemotherapy, used to treat lymphomas, carries a 10-15 fold increased risk of heart failure due to its cardiotoxic effects on cardiac function.

• The STOP-CA trial (Statins to Prevent CardiotOxicity Associated with Anthracyclines) was designed to test whether atorvastatin could protect cardiac function in patients receiving anthracycline therapy.

• Study inclusion criteria required participants to have Hodgkin's or non-Hodgkin's lymphoma, be scheduled for anthracycline therapy, and be 18 years or older, with strict exclusion criteria to maintain study integrity.

• The primary endpoint measured was a reduction in left ventricular ejection fraction of 10% or more (from approximately 60% down to 50%).

• Results showed compelling protection with the statin group: only 9% of atorvastatin-treated patients experienced significant cardiac dysfunction compared to 20% in the placebo group—more than twice the rate.

• The statin group demonstrated 2-3 times greater protection against progression to significant left ventricular dysfunction reduction compared to placebo.

• The protective mechanism is believed to involve statins' anti-inflammatory properties, which may mitigate inflammatory cellular responses triggered by chemotherapy.

• Cancer patients undergoing chemotherapy should discuss with their treating physicians whether starting or continuing statin therapy could provide cardiac protection.

• Those already taking statins who require chemotherapy may benefit from continuing statin therapy, pending specialist advice.